Evidence map›Paper›PMID 31270955›Full record

ArticleCancer medicine2019

Glioblastoma Multiforme in the over 70's: "To treat or not to treat with radiotherapy?"

Aisling M Glynn, Guhan Rangaswamy, Julianne O'Shea, Mary Dunne, Roger Grogan, Stephen MacNally, David Fitzpatrick, Clare Faul

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.3field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Radiotherapy for glioblastoma patients with poor performance status.Journal of cancer research and clinical oncology · 2022
    Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Aisling M GlynnSt Luke's Radiation Oncology Network, Dublin, Ireland.ORCID 0000-0003-1046-0513
Guhan RangaswamySt Luke's Radiation Oncology Network, Dublin, Ireland.
Julianne O'SheaSt Luke's Radiation Oncology Network, Dublin, Ireland.
Mary DunneSt Luke's Radiation Oncology Network, Dublin, Ireland.
Roger GroganDepartment of Neurosurgery, Beaumont Hospital, Dublin, Ireland.
Stephen MacNallyDepartment of Neurosurgery, Beaumont Hospital, Dublin, Ireland.
David FitzpatrickSt Luke's Radiation Oncology Network, Dublin, Ireland.
Clare FaulSt Luke's Radiation Oncology Network, Dublin, Ireland.
Beaumont Hospital · IE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe incidence of Glioblastoma Multiforme (GBM) is increasing among the older population and is associated with poor prognosis. Management guidelines are lacking in this group. The purpose of this study was to analyze survival data and determine predictors of survival in patients aged ≥70 years treated with radiotherapy (RT) and/or Temozolomide. MATERIALS AND

methodsA retrospective analysis of all GBM patients treated at our institution between January 2011 and January 2017 was carried out.

resultsOne-hundred and four patients were eligible. Median age was 73.8 years (70-87). Thirty-three patients received radical RT and 71 palliative RT. Overall median survival (MS) was 6 months. The MS was 10.6 months for radical patients and 4.9 months for palliative patients (P < 0.0005). The MS was 6.9 months in patients aged 70-75 years and 5.2 months in those aged 76-80 years (P = 0.004). The debulked group had a statistically significantly longer survival (8.0 months) than the biopsy only group (4.9 months). Biopsy only (hazard ratio [HR] 2.4), ECOG performance status 3 vs 0 (HR 6.4), and increasing age (HR 1.06) were associated with statistically significant shorter survival after adjustment for the effects of concurrent chemo, delay in starting RT, and RT dose.

conclusionThe MS for radical patients was favorable and approaching current literature for the under 70 age group. Radical treatment should be considered for good performance patients aged 70-75 years. Increasing age was associated with shorter MS in patients aged ≥76 years. Debulking and good performance status were associated with improved survival.

Indexed as

AgedAged, 80 and overAge DistributionAge FactorsBrain NeoplasmsClinical Decision-MakingFemaleGlioblastomaHumansMalePalliative CarePractice Guidelines as TopicRetrospective StudiesSeverity of Illness IndexSurvival AnalysisTime-to-TreatmentagedebulkingGlioblastomaperformance statusradiotherapyTemozolomide

Identifiers

PMID31270955
PMCPMC6712461
OpenAlexW2953554374

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.